C10AD52 • nicotinic acid + laropiprant • Cardiovascular system | Lipid modifying agents, plain | Nicotinic acid and derivatives
The combination of nicotinic acid and laropiprant is used to treat dyslipidemia, particularly to lower LDL cholesterol and triglycerides and increase HDL cholesterol. Laropiprant helps reduce the flushing side effect caused by nicotinic acid.
This combination is indicated for patients at high risk of cardiovascular diseases, especially when other treatments are not tolerated or effective. It is available in oral tablet form.
Side effects may include nausea, stomach discomfort, itching, or dizziness. Skin flushing is significantly reduced due to the presence of laropiprant.
Patients should inform their doctor about any liver conditions or other health issues before use. Monitoring liver function is recommended during treatment.
Substance: nicotinic acid + laropiprant
Date of last drug list: 01-07-2013
Commercial code: W53301012
Concentration: 1000mg / 20mg
Pharmaceutical form: modified release tablets
Quantity: 196
Product type: original
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).